Acquired L1196M ALK mutation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma during alectinib administration

EJHaem. 2023 Jan 24;4(1):305-308. doi: 10.1002/jha2.646. eCollection 2023 Feb.

Authors

Affiliations

¹ Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan.
² Department of Diagnostic Pathology Kanazawa University Hospital Kanazawa Japan.
³ Department of Pediatric Surgery Kanazawa University Hospital Kanazawa Japan.

No abstract available

Keywords: ALK‐positive anaplastic large cell lymphoma; L1196M ALK mutation; alectinib resistance; gatekeeper mutation; leukemic presentation.